WATPAC TO BUILD NUCLEAR FACILITY
Written on the 22 January 2014
WATPAC (ASX:WTP) will build an $83 million nuclear medicine facility at Lucas Heights.
Australian Nuclear Science and Technology Organisation (ANSTO) has contracted the Brisbane builder to construct the 4250sqm Nuclear Medicine Molybdenum-99 project.
When finished in 2016, the facility will supply the radioisotope molybdenum-99, which is used in 45 million nuclear medicine diagnostic procedures each year worldwide.
Watpac CEO Martin Monro (pictured) says the group has extensive experience in delivering complex health and science projects.
“During the past two years, Watpac Construction has delivered, or commenced work, on new health and science infrastructure totalling well in excess of $1 billion along Australia’s eastern seaboard,” he says.
Design work will commence in February. It will be required to meet the requirements of the Australian Radiation Protection and Nuclear Safety Agency and Australian Non-proliferation and Safeguards Office.
Recent WTP health and science projects include the $90 million Cochlear Global Headquarters in Sydney and the $240 million Translational Research Institute and Biopharmaceuticals Australia Biologics Plant of the Future in Brisbane.
Current projects include the $148 million Gold Coast Private Hospital, the $65 million Port Macquarie Base Hospital Expansion Project in New South Wales and the $40 million Phase 3 of the Queensland Institute of Medical Research in Brisbane.
The Group has also been awarded the Stage 1 managing contractor services for the new Mater Private Hospital Springfield, west of Brisbane.
WTP is trading up 2.01 per cent at $1.015 per unit this morning.